STERIS plc

What they do

STERIS provides consumables (detergents, endoscopy accessories, instruments), services (equipment maintenance, instrument repair, outsourced reprocessing, contract sterilization), and capital equipment (sterilizers, surgical tables, automated endoscope reprocessors). Its Healthcare segment serves hospitals and procedural centers; AST provides contract sterilization and laboratory services; Life Sciences supports pharmaceutical and medical device customers. The company operates globally, with revenue growth driven by aging populations and increased demand for medical procedures.

Revenue drivers

• Healthcare segment — Largest segment, generated $1.05 billion in Q1 FY2027 (8% growth). Revenue from consumables (9% growth), services (10%), and capital equipment (1%).
• Applied Sterilization Technologies (AST) — Generated $297.6 million in Q1 FY2027 (6% growth). Services (contract sterilization and lab) grew 6%; capital equipment declined 13%.
• Life Sciences segment — Generated $146.7 million in Q1 FY2027 (9% growth), with capital equipment up 17%, consumables up 8%, and services up 2%.
• Recurring revenues — Consumables and services are key recurring revenue streams, providing stable demand and growth across segments.

Recent performance

In Q1 FY2027 (ended June 30, 2026), total revenue rose 7% to $1.5 billion, with constant currency organic growth of 6%. Net income was $200.1 million, or $2.04 diluted EPS, up from $177.4 million ($1.79) in the prior-year quarter. Adjusted EPS was $2.59. Operating cash flow was $367.1 million, lower than $420.0 million due to a reduced working capital contribution. Full fiscal year 2026 (ended March 2026) revenue was $5.94 billion, net income $782.3 million, and diluted EPS $7.93.

Strategy

STERIS is investing in a new Formulated Chemistries Center of Excellence in North Carolina, with a targeted restructuring plan including closure of facilities in St. Louis and Plymouth to optimize the U.S. chemistries manufacturing and distribution network. Management emphasizes share gains in consumables and services, supported by solid capital equipment order growth. The company continues to focus on infection prevention and expanding its service offerings, including outsourced reprocessing and repair services. It aims to help customers navigate a complex operating environment while maintaining growth.

Risks

• Economic cyclicality — Adverse economic conditions or tight credit markets could reduce customer spending on capital equipment and consumables, hurting revenue.
• Government funding dependence — Many customers are governmental entities or rely on government healthcare funding; changes in policy or funding could reduce demand.
• Geopolitical conflicts — Ongoing global conflicts could exacerbate operational, supply chain, and regulatory risks, potentially affecting results.
• Tariff and inflation pressures — Increased tariff costs and inflation partly offset operating income growth in Q1 FY2027, and these pressures could continue.

Outlook

Management states that revenue and earnings expectations for fiscal 2027 are unchanged, citing stable underlying demand and strength in Healthcare consumables and services. The restructuring plan is expected to accelerate innovation and expand capacity, though it will incur pre-tax charges. Capital equipment order growth is solid, supporting future revenue.